Prognostic Value of Uric Acid in Predicting Metastasis Following Definitive Radiotherapy in Patients With Head and Neck Cancer.

IF 1.8 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

In vivo Pub Date : 2025-07-01 DOI:10.21873/invivo.14047

Sangmin Lee, Xue Li, Jin Ho Kim, Hong-Gyun Wu, Keun Yong Eom, Joo Ho Lee

{"title":"Prognostic Value of Uric Acid in Predicting Metastasis Following Definitive Radiotherapy in Patients With Head and Neck Cancer.","authors":"Sangmin Lee, Xue Li, Jin Ho Kim, Hong-Gyun Wu, Keun Yong Eom, Joo Ho Lee","doi":"10.21873/invivo.14047","DOIUrl":null,"url":null,"abstract":"Background/aim: This study investigated the prognostic value of serum uric acid (SUA) levels after definitive radiotherapy (RT) in head and neck cancer (HNC).Patients and methods: This retrospective study included patients with HNC undergoing definitive RT between January 2008 and February 2019. SUA levels were measured pre- and post-RT. Survival outcomes were analyzed using the Kaplan-Meier method, log-rank tests, and multivariable Cox regression. The optimal post-RT SUA cut-off (4.6 mg/dl) was determined via ROC analysis.Results: A total of 185 patients were analyzed, with a median follow-up of 63.3 months. The mean pre-treatment SUA level was 5.4 mg/dl, which decreased to 5.2 mg/dl post-treatment, though the difference was not statistically significant (p=0.326). A post-treatment SUA cut-off of 4.6 mg/dl demonstrated discriminatory ability for distant metastasis-free survival (DMFS) but was not predictive of overall survival or locoregional relapse-free survival (LRFS). Kaplan-Meier analysis showed that patients with post-treatment SUA ≥4.6 mg/dl had significantly poorer DMFS than those with lower levels [hazard ratio (HR)=1.25, 95% confidence interval (CI)=1.02-1.53; p=0.004]. Multivariable analysis confirmed post-treatment SUA ≥4.6 mg/dl (HR=5.01, p=0.010), HPV-negative oropharyngeal tumors (HR=5.68, p=0.025), and Stage IV disease (HR=4.10, p=0.020) as independent prognostic factors for DMFS.Conclusion: Post-treatment SUA levels may serve as a potential marker for predicting metastasis following RT in HNC.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2464-2473"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223636/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14047","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: This study investigated the prognostic value of serum uric acid (SUA) levels after definitive radiotherapy (RT) in head and neck cancer (HNC).

Patients and methods: This retrospective study included patients with HNC undergoing definitive RT between January 2008 and February 2019. SUA levels were measured pre- and post-RT. Survival outcomes were analyzed using the Kaplan-Meier method, log-rank tests, and multivariable Cox regression. The optimal post-RT SUA cut-off (4.6 mg/dl) was determined via ROC analysis.

Results: A total of 185 patients were analyzed, with a median follow-up of 63.3 months. The mean pre-treatment SUA level was 5.4 mg/dl, which decreased to 5.2 mg/dl post-treatment, though the difference was not statistically significant (p=0.326). A post-treatment SUA cut-off of 4.6 mg/dl demonstrated discriminatory ability for distant metastasis-free survival (DMFS) but was not predictive of overall survival or locoregional relapse-free survival (LRFS). Kaplan-Meier analysis showed that patients with post-treatment SUA ≥4.6 mg/dl had significantly poorer DMFS than those with lower levels [hazard ratio (HR)=1.25, 95% confidence interval (CI)=1.02-1.53; p=0.004]. Multivariable analysis confirmed post-treatment SUA ≥4.6 mg/dl (HR=5.01, p=0.010), HPV-negative oropharyngeal tumors (HR=5.68, p=0.025), and Stage IV disease (HR=4.10, p=0.020) as independent prognostic factors for DMFS.

Conclusion: Post-treatment SUA levels may serve as a potential marker for predicting metastasis following RT in HNC.

查看原文本刊更多论文

尿酸在预测头颈部肿瘤放疗后转移中的预后价值。

背景/目的：本研究探讨头颈癌（HNC）放疗后血清尿酸（SUA）水平的预后价值。患者和方法：本回顾性研究纳入了2008年1月至2019年2月期间接受终期放疗的HNC患者。分别在放疗前和放疗后测量SUA水平。生存结局采用Kaplan-Meier法、log-rank检验和多变量Cox回归分析。通过ROC分析确定最佳rt后SUA临界值（4.6 mg/dl）。结果：共分析185例患者，中位随访时间为63.3个月。治疗前平均SUA水平为5.4 mg/dl，治疗后降至5.2 mg/dl，但差异无统计学意义（p=0.326）。治疗后的SUA截止值为4.6 mg/dl，显示了对远处无转移生存（DMFS）的区分能力，但不能预测总生存或局部无复发生存（LRFS）。Kaplan-Meier分析显示，治疗后SUA≥4.6 mg/dl的患者DMFS明显差于SUA水平较低的患者[风险比(HR)=1.25, 95%可信区间(CI)=1.02-1.53；p = 0.004)。多变量分析证实，治疗后SUA≥4.6 mg/dl （HR=5.01, p=0.010）、hpv阴性口咽肿瘤（HR=5.68, p=0.025）和IV期疾病（HR=4.10, p=0.020）是DMFS的独立预后因素。结论：治疗后SUA水平可作为预测HNC RT后转移的潜在标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

In vivo 医学-医学：研究与实验

CiteScore

4.20

自引率

4.30%

发文量

330

审稿时长

3-8 weeks

期刊介绍： IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.